Dual inhibition of LAG-3 and PD-1 in patients with previously untreated metastatic or unresectable melanoma
Grey Horizon,
Findings from a recent phase II/III trial, RELATIVITY-047, evaluating "dual inhibition of LAG-3 and PD-1 using a new…
Findings from a recent phase II/III trial, RELATIVITY-047, evaluating "dual inhibition of LAG-3 and PD-1 using a new…
THURSDAY, Jan. 6, 2022 (HealthDay News) — For patients with previously untreated metastatic or unresectable melanoma, the…
THURSDAY, Jan. 6, 2022 (HealthDay News) — For patients with previously untreated metastatic or unresectable melanoma, the…
Combo more than doubles PFS in RELATIVITY-047 The combination of relatlimab and nivolumab was found to more than double…